Goldman Sachs reaffirms buy on Eli Lilly and Company (LLY), citing 25% growth outlook
I'm PortAI, I can summarize articles.
Goldman Sachs has reaffirmed its Buy rating on Eli Lilly and Company (NYSE:LLY), raising its price target from $1,145 to $1,260, citing a 25% growth outlook. Eli Lilly is also listed among the 13 Best Long Term Low Risk Stocks to Buy Now. Following the announcement, shares of Eli Lilly surged approximately 10%.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments